The global market for HIV Vaccine was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

AIDS, or Acquired Immunodeficiency Syndrome (AIDS), is caused by the human immunodeficiency virus (HIV), also known as the AIDS virus. HIV can specifically attack and destroy human immune cells, causing damage to the human immune system, gradual loss of related immune functions, and gradually becoming the target of many diseases, leading to various serious opportunistic infections, tumors, etc. At present, AIDS has become an important public health issue that seriously threatens the health of people around the world. In 1981, doctors discovered the first known case of HIV in the United States, and since then, more than 40 million people have died from the virus. According to data from the United Nations AIDS Program, men who have sex with men, female sex workers and their clients, transgender people, and people who inject drugs are at high risk. The virus is transmitted through the exchange of body fluids of infected people, such as blood, semen, and vaginal excrement. The most common is during unprotected sex, pregnancy and childbirth, transfusion of contaminated blood, or sharing of hypodermic needles. The human body cannot completely eliminate HIV. Therefore, once infected with the virus, an individual will remain HIV positive for life. However, through antiretroviral therapy (ART) drug treatment, HIV can be controlled, its progression can be significantly slowed, and gradually become a "chronic disease". In theory, before the emergence of curative drugs, AIDS patients need to take medication for life. Although there are relatively many existing antiviral therapies, they all have a clear disadvantage: long taking cycles and short intervals. Once the medication is stopped or missed, it will lead to the deterioration of AIDS; and long-term medication may also cause problems such as drug resistance and liver damage. Historically, vaccines have been the most effective means of preventing or even eradicating infectious diseases. They can safely and cost-effectively prevent disease, disability and death. HIV vaccine is a potential vaccine that can be both a preventive vaccine and a therapeutic vaccine, meaning that it can protect individuals from HIV infection and treat HIV-infected people. In theory, it can have a significant impact on transmission rates and help control epidemics.

North American market for HIV Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for HIV Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of HIV Vaccine include Johnson and Johnson (Janssen), Sanofi-Pasteur, Uvax Bio, AELIX Therapeutics, IAVI, HKUMed, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for HIV Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HIV Vaccine.

The HIV Vaccine market size, estimations, and forecasts are provided in terms of sales volume (Million Person) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global HIV Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the HIV Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of HIV Vaccine Market Report

Report Metric	Details
Report Name	HIV Vaccine Market
Segment by Type	Viral Vector Vaccines Recombinant Protein Vaccines Nucleic Acid Vaccines (including mRNA Vaccines) Other Vaccines
Segment by Application	Preventive Vaccine Therapeutic Vaccine
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Johnson and Johnson (Janssen), Sanofi-Pasteur, Uvax Bio, AELIX Therapeutics, IAVI, HKUMed
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of HIV Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of HIV Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the HIV Vaccine Market report?

Ans: The main players in the HIV Vaccine Market are Johnson and Johnson (Janssen), Sanofi-Pasteur, Uvax Bio, AELIX Therapeutics, IAVI, HKUMed

What are the Application segmentation covered in the HIV Vaccine Market report?

Ans: The Applications covered in the HIV Vaccine Market report are Preventive Vaccine, Therapeutic Vaccine

What are the Type segmentation covered in the HIV Vaccine Market report?

Ans: The Types covered in the HIV Vaccine Market report are Viral Vector Vaccines, Recombinant Protein Vaccines, Nucleic Acid Vaccines (including mRNA Vaccines), Other Vaccines

1 HIV Vaccine Market Overview

1.1 Product Definition

1.2 HIV Vaccine by Type

1.2.1 Global HIV Vaccine Market Value Comparison by Type (2024 VS 2031)

1.2.2 Viral Vector Vaccines

1.2.3 Recombinant Protein Vaccines

1.2.4 Nucleic Acid Vaccines (including mRNA Vaccines)

1.2.5 Other Vaccines

1.3 HIV Vaccine by Application

1.3.1 Global HIV Vaccine Market Value by Application (2024 VS 2031)

1.3.2 Preventive Vaccine

1.3.3 Therapeutic Vaccine

1.4 Global HIV Vaccine Market Size Estimates and Forecasts

1.4.1 Global HIV Vaccine Revenue 2020-2031

1.4.2 Global HIV Vaccine Sales 2020-2031

1.4.3 Global HIV Vaccine Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 HIV Vaccine Market Competition by Manufacturers

2.1 Global HIV Vaccine Sales Market Share by Manufacturers (2020-2025)

2.2 Global HIV Vaccine Revenue Market Share by Manufacturers (2020-2025)

2.3 Global HIV Vaccine Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of HIV Vaccine, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of HIV Vaccine, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of HIV Vaccine, Product Type & Application

2.7 Global Key Manufacturers of HIV Vaccine, Date of Enter into This Industry

2.8 Global HIV Vaccine Market Competitive Situation and Trends

2.8.1 Global HIV Vaccine Market Concentration Rate

2.8.2 The Global 5 and 10 Largest HIV Vaccine Players Market Share by Revenue

2.8.3 Global HIV Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global HIV Vaccine Market Scenario by Region

3.1 Global HIV Vaccine Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global HIV Vaccine Sales by Region: 2020-2031

3.2.1 Global HIV Vaccine Sales by Region: 2020-2025

3.2.2 Global HIV Vaccine Sales by Region: 2026-2031

3.3 Global HIV Vaccine Revenue by Region: 2020-2031

3.3.1 Global HIV Vaccine Revenue by Region: 2020-2025

3.3.2 Global HIV Vaccine Revenue by Region: 2026-2031

3.4 North America HIV Vaccine Market Facts & Figures by Country

3.4.1 North America HIV Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America HIV Vaccine Sales by Country (2020-2031)

3.4.3 North America HIV Vaccine Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe HIV Vaccine Market Facts & Figures by Country

3.5.1 Europe HIV Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe HIV Vaccine Sales by Country (2020-2031)

3.5.3 Europe HIV Vaccine Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific HIV Vaccine Market Facts & Figures by Region

3.6.1 Asia Pacific HIV Vaccine Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific HIV Vaccine Sales by Region (2020-2031)

3.6.3 Asia Pacific HIV Vaccine Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America HIV Vaccine Market Facts & Figures by Country

3.7.1 Latin America HIV Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America HIV Vaccine Sales by Country (2020-2031)

3.7.3 Latin America HIV Vaccine Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa HIV Vaccine Market Facts & Figures by Country

3.8.1 Middle East and Africa HIV Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa HIV Vaccine Sales by Country (2020-2031)

3.8.3 Middle East and Africa HIV Vaccine Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global HIV Vaccine Sales by Type (2020-2031)

4.1.1 Global HIV Vaccine Sales by Type (2020-2025)

4.1.2 Global HIV Vaccine Sales by Type (2026-2031)

4.1.3 Global HIV Vaccine Sales Market Share by Type (2020-2031)

4.2 Global HIV Vaccine Revenue by Type (2020-2031)

4.2.1 Global HIV Vaccine Revenue by Type (2020-2025)

4.2.2 Global HIV Vaccine Revenue by Type (2026-2031)

4.2.3 Global HIV Vaccine Revenue Market Share by Type (2020-2031)

4.3 Global HIV Vaccine Price by Type (2020-2031)

5 Segment by Application

5.1 Global HIV Vaccine Sales by Application (2020-2031)

5.1.1 Global HIV Vaccine Sales by Application (2020-2025)

5.1.2 Global HIV Vaccine Sales by Application (2026-2031)

5.1.3 Global HIV Vaccine Sales Market Share by Application (2020-2031)

5.2 Global HIV Vaccine Revenue by Application (2020-2031)

5.2.1 Global HIV Vaccine Revenue by Application (2020-2025)

5.2.2 Global HIV Vaccine Revenue by Application (2026-2031)

5.2.3 Global HIV Vaccine Revenue Market Share by Application (2020-2031)

5.3 Global HIV Vaccine Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Johnson and Johnson (Janssen)

6.1.1 Johnson and Johnson (Janssen) Company Information

6.1.2 Johnson and Johnson (Janssen) Description and Business Overview

6.1.3 Johnson and Johnson (Janssen) HIV Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Johnson and Johnson (Janssen) HIV Vaccine Product Portfolio

6.1.5 Johnson and Johnson (Janssen) Recent Developments/Updates

6.2 Sanofi-Pasteur

6.2.1 Sanofi-Pasteur Company Information

6.2.2 Sanofi-Pasteur Description and Business Overview

6.2.3 Sanofi-Pasteur HIV Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Sanofi-Pasteur HIV Vaccine Product Portfolio

6.2.5 Sanofi-Pasteur Recent Developments/Updates

6.3 Uvax Bio

6.3.1 Uvax Bio Company Information

6.3.2 Uvax Bio Description and Business Overview

6.3.3 Uvax Bio HIV Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Uvax Bio HIV Vaccine Product Portfolio

6.3.5 Uvax Bio Recent Developments/Updates

6.4 AELIX Therapeutics

6.4.1 AELIX Therapeutics Company Information

6.4.2 AELIX Therapeutics Description and Business Overview

6.4.3 AELIX Therapeutics HIV Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.4.4 AELIX Therapeutics HIV Vaccine Product Portfolio

6.4.5 AELIX Therapeutics Recent Developments/Updates

6.5 IAVI

6.5.1 IAVI Company Information

6.5.2 IAVI Description and Business Overview

6.5.3 IAVI HIV Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.5.4 IAVI HIV Vaccine Product Portfolio

6.5.5 IAVI Recent Developments/Updates

6.6 HKUMed

6.6.1 HKUMed Company Information

6.6.2 HKUMed Description and Business Overview

6.6.3 HKUMed HIV Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.6.4 HKUMed HIV Vaccine Product Portfolio

6.6.5 HKUMed Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 HIV Vaccine Industry Chain Analysis

7.2 HIV Vaccine Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 HIV Vaccine Production Mode & Process Analysis

7.4 HIV Vaccine Sales and Marketing

7.4.1 HIV Vaccine Sales Channels

7.4.2 HIV Vaccine Distributors

7.5 HIV Vaccine Customer Analysis

8 HIV Vaccine Market Dynamics

8.1 HIV Vaccine Industry Trends

8.2 HIV Vaccine Market Drivers

8.3 HIV Vaccine Market Challenges

8.4 HIV Vaccine Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Uvax Bio

Johnson and Johnson (Janssen)

List of Tables

Table 1. Global HIV Vaccine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global HIV Vaccine Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global HIV Vaccine Market Competitive Situation by Manufacturers in 2024

Table 4. Global HIV Vaccine Sales (Million Person) of Key Manufacturers (2020-2025)

Table 5. Global HIV Vaccine Sales Market Share by Manufacturers (2020-2025)

Table 6. Global HIV Vaccine Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global HIV Vaccine Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market HIV Vaccine Average Price (US$/Person) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of HIV Vaccine, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of HIV Vaccine, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of HIV Vaccine, Product Type & Application

Table 12. Global Key Manufacturers of HIV Vaccine, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global HIV Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HIV Vaccine as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global HIV Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global HIV Vaccine Sales by Region (2020-2025) & (Million Person)

Table 18. Global HIV Vaccine Sales Market Share by Region (2020-2025)

Table 19. Global HIV Vaccine Sales by Region (2026-2031) & (Million Person)

Table 20. Global HIV Vaccine Sales Market Share by Region (2026-2031)

Table 21. Global HIV Vaccine Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global HIV Vaccine Revenue Market Share by Region (2020-2025)

Table 23. Global HIV Vaccine Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global HIV Vaccine Revenue Market Share by Region (2026-2031)

Table 25. North America HIV Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America HIV Vaccine Sales by Country (2020-2025) & (Million Person)

Table 27. North America HIV Vaccine Sales by Country (2026-2031) & (Million Person)

Table 28. North America HIV Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America HIV Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe HIV Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe HIV Vaccine Sales by Country (2020-2025) & (Million Person)

Table 32. Europe HIV Vaccine Sales by Country (2026-2031) & (Million Person)

Table 33. Europe HIV Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe HIV Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific HIV Vaccine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific HIV Vaccine Sales by Region (2020-2025) & (Million Person)

Table 37. Asia Pacific HIV Vaccine Sales by Region (2026-2031) & (Million Person)

Table 38. Asia Pacific HIV Vaccine Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific HIV Vaccine Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America HIV Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America HIV Vaccine Sales by Country (2020-2025) & (Million Person)

Table 42. Latin America HIV Vaccine Sales by Country (2026-2031) & (Million Person)

Table 43. Latin America HIV Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America HIV Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa HIV Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa HIV Vaccine Sales by Country (2020-2025) & (Million Person)

Table 47. Middle East and Africa HIV Vaccine Sales by Country (2026-2031) & (Million Person)

Table 48. Middle East and Africa HIV Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa HIV Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global HIV Vaccine Sales (Million Person) by Type (2020-2025)

Table 51. Global HIV Vaccine Sales (Million Person) by Type (2026-2031)

Table 52. Global HIV Vaccine Sales Market Share by Type (2020-2025)

Table 53. Global HIV Vaccine Sales Market Share by Type (2026-2031)

Table 54. Global HIV Vaccine Revenue (US$ Million) by Type (2020-2025)

Table 55. Global HIV Vaccine Revenue (US$ Million) by Type (2026-2031)

Table 56. Global HIV Vaccine Revenue Market Share by Type (2020-2025)

Table 57. Global HIV Vaccine Revenue Market Share by Type (2026-2031)

Table 58. Global HIV Vaccine Price (US$/Person) by Type (2020-2025)

Table 59. Global HIV Vaccine Price (US$/Person) by Type (2026-2031)

Table 60. Global HIV Vaccine Sales (Million Person) by Application (2020-2025)

Table 61. Global HIV Vaccine Sales (Million Person) by Application (2026-2031)

Table 62. Global HIV Vaccine Sales Market Share by Application (2020-2025)

Table 63. Global HIV Vaccine Sales Market Share by Application (2026-2031)

Table 64. Global HIV Vaccine Revenue (US$ Million) by Application (2020-2025)

Table 65. Global HIV Vaccine Revenue (US$ Million) by Application (2026-2031)

Table 66. Global HIV Vaccine Revenue Market Share by Application (2020-2025)

Table 67. Global HIV Vaccine Revenue Market Share by Application (2026-2031)

Table 68. Global HIV Vaccine Price (US$/Person) by Application (2020-2025)

Table 69. Global HIV Vaccine Price (US$/Person) by Application (2026-2031)

Table 70. Johnson and Johnson (Janssen) Company Information

Table 71. Johnson and Johnson (Janssen) Description and Business Overview

Table 72. Johnson and Johnson (Janssen) HIV Vaccine Sales (Million Person), Revenue (US$ Million), Price (US$/Person) and Gross Margin (2020-2025)

Table 73. Johnson and Johnson (Janssen) HIV Vaccine Product

Table 74. Johnson and Johnson (Janssen) Recent Developments/Updates

Table 75. Sanofi-Pasteur Company Information

Table 76. Sanofi-Pasteur Description and Business Overview

Table 77. Sanofi-Pasteur HIV Vaccine Sales (Million Person), Revenue (US$ Million), Price (US$/Person) and Gross Margin (2020-2025)

Table 78. Sanofi-Pasteur HIV Vaccine Product

Table 79. Sanofi-Pasteur Recent Developments/Updates

Table 80. Uvax Bio Company Information

Table 81. Uvax Bio Description and Business Overview

Table 82. Uvax Bio HIV Vaccine Sales (Million Person), Revenue (US$ Million), Price (US$/Person) and Gross Margin (2020-2025)

Table 83. Uvax Bio HIV Vaccine Product

Table 84. Uvax Bio Recent Developments/Updates

Table 85. AELIX Therapeutics Company Information

Table 86. AELIX Therapeutics Description and Business Overview

Table 87. AELIX Therapeutics HIV Vaccine Sales (Million Person), Revenue (US$ Million), Price (US$/Person) and Gross Margin (2020-2025)

Table 88. AELIX Therapeutics HIV Vaccine Product

Table 89. AELIX Therapeutics Recent Developments/Updates

Table 90. IAVI Company Information

Table 91. IAVI Description and Business Overview

Table 92. IAVI HIV Vaccine Sales (Million Person), Revenue (US$ Million), Price (US$/Person) and Gross Margin (2020-2025)

Table 93. IAVI HIV Vaccine Product

Table 94. IAVI Recent Developments/Updates

Table 95. HKUMed Company Information

Table 96. HKUMed Description and Business Overview

Table 97. HKUMed HIV Vaccine Sales (Million Person), Revenue (US$ Million), Price (US$/Person) and Gross Margin (2020-2025)

Table 98. HKUMed HIV Vaccine Product

Table 99. HKUMed Recent Developments/Updates

Table 100. Key Raw Materials Lists

Table 101. Raw Materials Key Suppliers Lists

Table 102. HIV Vaccine Distributors List

Table 103. HIV Vaccine Customers List

Table 104. HIV Vaccine Market Trends

Table 105. HIV Vaccine Market Drivers

Table 106. HIV Vaccine Market Challenges

Table 107. HIV Vaccine Market Restraints

Table 108. Research Programs/Design for This Report

Table 109. Key Data Information from Secondary Sources

Table 110. Key Data Information from Primary Sources

Table 111. Authors List of This Report

List of Figures

Figure 1. Product Picture of HIV Vaccine

Figure 2. Global HIV Vaccine Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global HIV Vaccine Market Share by Type: 2024 & 2031

Figure 4. Viral Vector Vaccines Product Picture

Figure 5. Recombinant Protein Vaccines Product Picture

Figure 6. Nucleic Acid Vaccines (including mRNA Vaccines) Product Picture

Figure 7. Other Vaccines Product Picture

Figure 8. Global HIV Vaccine Market Value by Application (2020-2031) & (US$ Million)

Figure 9. Global HIV Vaccine Market Share by Application: 2024 & 2031

Figure 10. Preventive Vaccine

Figure 11. Therapeutic Vaccine

Figure 12. Global HIV Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global HIV Vaccine Market Size (2020-2031) & (US$ Million)

Figure 14. Global HIV Vaccine Sales (2020-2031) & (Million Person)

Figure 15. Global HIV Vaccine Average Price (US$/Person) & (2020-2031)

Figure 16. HIV Vaccine Report Years Considered

Figure 17. HIV Vaccine Sales Share by Manufacturers in 2024

Figure 18. Global HIV Vaccine Revenue Share by Manufacturers in 2024

Figure 19. Global 5 and 10 Largest HIV Vaccine Players: Market Share by Revenue in HIV Vaccine in 2024

Figure 20. HIV Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 21. Global HIV Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 22. North America HIV Vaccine Sales Market Share by Country (2020-2031)

Figure 23. North America HIV Vaccine Revenue Market Share by Country (2020-2031)

Figure 24. United States HIV Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 25. Canada HIV Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 26. Europe HIV Vaccine Sales Market Share by Country (2020-2031)

Figure 27. Europe HIV Vaccine Revenue Market Share by Country (2020-2031)

Figure 28. Germany HIV Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. France HIV Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. U.K. HIV Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Italy HIV Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Russia HIV Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Asia Pacific HIV Vaccine Sales Market Share by Region (2020-2031)

Figure 34. Asia Pacific HIV Vaccine Revenue Market Share by Region (2020-2031)

Figure 35. China HIV Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Japan HIV Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. South Korea HIV Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. India HIV Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Australia HIV Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. China Taiwan HIV Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Southeast Asia HIV Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Latin America HIV Vaccine Sales Market Share by Country (2020-2031)

Figure 43. Latin America HIV Vaccine Revenue Market Share by Country (2020-2031)

Figure 44. Mexico HIV Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Brazil HIV Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Argentina HIV Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Middle East and Africa HIV Vaccine Sales Market Share by Country (2020-2031)

Figure 48. Middle East and Africa HIV Vaccine Revenue Market Share by Country (2020-2031)

Figure 49. Turkey HIV Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Saudi Arabia HIV Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. UAE HIV Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Global Sales Market Share of HIV Vaccine by Type (2020-2031)

Figure 53. Global Revenue Market Share of HIV Vaccine by Type (2020-2031)

Figure 54. Global HIV Vaccine Price (US$/Person) by Type (2020-2031)

Figure 55. Global Sales Market Share of HIV Vaccine by Application (2020-2031)

Figure 56. Global Revenue Market Share of HIV Vaccine by Application (2020-2031)

Figure 57. Global HIV Vaccine Price (US$/Person) by Application (2020-2031)

Figure 58. HIV Vaccine Value Chain

Figure 59. Channels of Distribution (Direct Vs Distribution)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions